RNAIII-inhibiting peptide(TFA)

Name: RNAIII-inhibiting peptide(TFA)
Brand: MedChemExpress
SKU: HY-P1452A
Rating: 4.5 (1 reviews)

Cat. No.: HY-P1452A Purity: 99.19%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

RNAIII-inhibiting peptide(TFA) Chemical Structure

CAS No. : 2703745-76-8

Size	Price	Stock	Quantity
1 mg	USD 100	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 210	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 310	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis.

IC₅₀ & Target

Staphylococcus aureus^[1]

In Vitro

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus. RNAIII-inhibiting peptide (RIP) inhibits the synthesis of both RNAII and RNAIII, while RAP activates in wild type S. aureus cells. RNAIII-inhibiting peptide (5 μg/10⁶ cells) potently reduces bacterial cell adhesion to HEp2 cells in the absence of serum, but with slight overall reduction the presence of serum. RNAIII-inhibiting peptide inhibits while RAP induces the phosphorylation of TRAP^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

RNAIII-inhibiting peptide (20 mg/kg, i.v.) decreases lethality in mice challenged with S. aureus ATCC 25923, with the lethality rate of 70%, and when combined with cefazolin, imipenem, vancomycin, the rates are 20%, 15% and 10%. RNAIII-inhibiting peptide (20 mg/kg, i.v.) also causes decreased lethality in mice challenged with S. aureus Smith, with the lethality rate of 75%, and the lethality rate decreases to 30%, 10% and 10% when combined with cefazolin, imipenem, vancomycin^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

1027.01

Formula

C₄₇H₅₇F₃N₁₀O₁₃

CAS No.

2703745-76-8

Appearance

Solid

Color

White to off-white

Sequence

Tyr-Ser-Pro-Trp-Thr-Asn-Phe-NH2

Sequence Shortening

YSPWTNF-NH2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 150 mg/mL (146.06 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 100 mg/mL (97.37 mM; Need ultrasonic)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.9737 mL	4.8685 mL	9.7370 mL
5 mM	0.1947 mL	0.9737 mL	1.9474 mL
10 mM	0.0974 mL	0.4869 mL	0.9737 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.19%

Select Batch:

Data Sheet (283 KB) SDS (252 KB)

COA (261 KB) RP-HPLC (110 KB) MS (217 KB) Elemental Analysis Report (121 KB)

Handling Instructions (2659 KB)

References

[1]. Gov Y, et al. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides. 2001 Oct;22(10):1609-20. [Content Brief]

[2]. Giacometti A, et al. RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. Peptides. 2005 Feb;26(2):169-75. [Content Brief]

Animal Administration
^[2]

Mice^[2]
Mice are randomized to receive intravenously isotonic sodium chloride solution (controls C1 and C2) and 20 mg/kg RNAIII-inhibiting peptide alone or combined with 20 mg/kg cefazolin, 10 mg/kg imipenem, or 10 mg/kg vancomycin. Animals are returned to individual cages and monitored for 7 days. The endpoints of the study are quantitative plasma bacterial evaluation and lethality. For each animal model, toxicity is evaluated on the basis of the presence of any drug-related adverse effects, i.e. local signs of inflammation, anorexia, weight loss, vomiting, diarrhea, fever, and behavioral alterations. In particular, to evaluate the physiological effects of RNAIII-inhibiting peptide, temperature, pulse, blood pressure, respirations and oxygenation are monitored in a supplementary RNAIII-inhibiting peptide-treated group without infection^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Gov Y, et al. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides. 2001 Oct;22(10):1609-20. [Content Brief]

[2]. Giacometti A, et al. RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis. Peptides. 2005 Feb;26(2):169-75. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	0.9737 mL	4.8685 mL	9.7370 mL	24.3425 mL
	5 mM	0.1947 mL	0.9737 mL	1.9474 mL	4.8685 mL
	10 mM	0.0974 mL	0.4869 mL	0.9737 mL	2.4343 mL
	15 mM	0.0649 mL	0.3246 mL	0.6491 mL	1.6228 mL
	20 mM	0.0487 mL	0.2434 mL	0.4869 mL	1.2171 mL
	25 mM	0.0389 mL	0.1947 mL	0.3895 mL	0.9737 mL
	30 mM	0.0325 mL	0.1623 mL	0.3246 mL	0.8114 mL
	40 mM	0.0243 mL	0.1217 mL	0.2434 mL	0.6086 mL
	50 mM	0.0195 mL	0.0974 mL	0.1947 mL	0.4869 mL
	60 mM	0.0162 mL	0.0811 mL	0.1623 mL	0.4057 mL
	80 mM	0.0122 mL	0.0609 mL	0.1217 mL	0.3043 mL
DMSO	100 mM	0.0097 mL	0.0487 mL	0.0974 mL	0.2434 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.